2026 ICD-10-CM Diagnosis Code T38.0X5SAdverse effect of glucocorticoids and synthetic analogues, sequela
T38.0X5S is a billable ICD-10-CM diagnosis code for adverse effect of glucocorticoids and synthetic analogues, sequela. The 7th character S marks it as a sequela code, which reports a problem that remains after the original condition has resolved. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 922 through 923. The code is not accepted as a principal diagnosis by the Medicare Code Editor and exempt from POA reporting. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Poisoning/toxic effect/adverse effects/underdosing, sequela.
Code Identity
Code Classification
Code EditsBilling
Medicare Code Editor checks that affect claim validity for T38.0X5S.
Present on Admission (POA)Billing
T38.0X5S is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Acne of external chemical origin
- ACTH deficiency
- Adverse reaction following injection of substance
- Atrophy of skin caused by drug
- Atrophy of skin caused by systemic corticosteroid
- Bilateral glaucoma suspect
- Bilateral ocular hypertension caused by corticosteroid
- Cataract of left eye caused by corticosteroid
- Cataract of left eye caused by medication
- Cataract of right eye caused by corticosteroid
- Cataract of right eye caused by medication
- Corticosteroid induced cataract
- Corticosteroid withdrawal syndrome following therapeutic use
- Corticosteroid-induced neutrophilia
- Corticosteroid-induced open angle glaucoma
- Corticosteroid-induced telangiectasia
- Corticosteroids adverse reaction
- Cortisone adverse reaction
- Cushingoid facies
- Cutaneous atrophy caused by corticosteroids
- Desoxymethasone adverse reaction
- Dexamethasone adverse reaction
- Diabetes mellitus caused by chemical
- Drug-induced cataract
- Drug-induced diabetes mellitus
- Drug-induced hyperglycemia
- Drug-induced immunodeficiency
- Drug-induced neutrophilia
- Drug-induced ocular hypertension
- Drug-induced open angle glaucoma
- Drug-induced open angle glaucoma of left eye
- Drug-induced open angle glaucoma of right eye
- Drug-induced osteoporosis
- Drug-induced panniculitis
- Drug-induced telangiectasia
- Glaucoma suspect caused by corticosteroid
- Glaucoma suspect of bilateral eyes caused by corticosteroid
- Glaucoma suspect of left eye
- Glaucoma suspect of left eye caused by corticosteroid
- Glaucoma suspect of right eye
- Glaucoma suspect of right eye caused by corticosteroid
- Hyperlipidemia caused by steroid
- Immunodeficiency secondary to corticosteroid
- Intra-articular steroid-induced arthritis and periarthritis
- Lipoatrophy caused by injected corticosteroid
- Lipoatrophy caused by injected drug
- Localized lipoatrophy
- Methylprednisolone adverse reaction
- Neutrophilia disorder
- Ocular hypertension of left eye caused by corticosteroid
- Ocular hypertension of right eye caused by corticosteroid
- Open angle glaucoma of left eye caused by corticosteroid
- Open angle glaucoma of right eye caused by corticosteroid
- Osteonecrosis caused by glucocorticoid
- Osteoporosis caused by corticosteroid
- Panniculitis caused by corticosteroid therapy
- Perioral dermatitis caused by corticosteroid
- Prednisolone adverse reaction
- Prednisone adverse reaction
- Rectal prednisolone preparations adverse reaction
- Rosacea caused by topical corticosteroid
- Secondary hyperlipidemia
- Secondary ocular hypertension caused by corticosteroid
- Skin disease attributable to corticosteroid therapy
- Stellate pseudoscar
- Stellate pseudoscar caused by corticosteroid
- Steroid acne
- Steroid hormone withdrawal syndrome following therapeutic use
- Steroid suppression of ACTH secretion
- Steroidal ecchymosis
- Steroid-induced diabetes
- Steroid-induced glaucoma glaucomatous stage
- Steroid-induced hyperglycemia
- Steroid-induced myopathy
- Steroid-induced osteopenia
- Steroid-modified tinea infection
- Steroid-modified tinea infection of foot
- Steroid-modified tinea infection of lower limb
- Tinea pedis
- Toxic cataract
Coding GuidelinesGuidance
When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.
The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of hormones and their synthetic substitutes and antagonists, not elsewhere classified (T38). Use the following options for the applicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Tinea Pedis
dermatological pruritic lesion in the feet, caused by trichophyton rubrum, t. mentagrophytes, or epidermophyton floccosum.
Table of Drugs and ChemicalsClinical
Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.
Patient EducationClinical
Drug Reactions
Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.
The full article covers:
- What is a drug interaction?
- What are side effects?
- What are drug allergies?
- How can I stay safe when taking medicines?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert T38.0X5S to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About T38.0X5SOverview
Is T38.0X5S (Adverse effect of glucocorticoids and synthetic analogues) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report adverse effect of glucocorticoids and synthetic analogues, sequela on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What does the 7th character S in T38.0X5S mean?
The final character S makes this a sequela code: it reports a lingering problem that remains after the adverse effect of glucocorticoids and synthetic analogues itself has resolved, not the original event.
What MS-DRG does T38.0X5S group to?
On inpatient claims, adverse effect of glucocorticoids and synthetic analogues, sequela maps to MS-DRG 922, 923, with relative weights from 1.0177 to 1.7494 depending on complications. Higher weights mean higher Medicare reimbursement.
Can T38.0X5S be a principal diagnosis?
No. The Medicare Code Editor rejects this code as a principal diagnosis because adverse effect of glucocorticoids and synthetic analogues, sequela describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.
Is T38.0X5S exempt from POA reporting?
Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for adverse effect of glucocorticoids and synthetic analogues, sequela on inpatient claims.
Footnotes
[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.
